Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
ImmunoGen Inc Market Cap
From what 9 stock analysts predict, the share price for ImmunoGen Inc (IMGN) might decrease by 0.45% in the next year. This is based on a 12-month average estimation for IMGN. Price targets go from $31.00 to $31.26. The majority of stock analysts believe IMGN is a hold. Please note analyst price targets are not guaranteed and could be missed completely.
ImmunoGen Inc has a total of 9 Wall St Analyst ratings. There are 0 buy ratings, 9 ratings, and 0 sell ratings. Since most analysts have a hold consensus rating, the expectation is that ImmunoGen Inc will generate similar returns as the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| michael schmidt Guggenheim | Hold | None | rated | Dec 20, 2023 |
| john newman Canaccord Genuity | Hold | $31.26 | maintained | Dec 5, 2023 |
| joseph catanzaro Piper Sandler | Hold | $31.0 | downgraded | Dec 4, 2023 |
| peter lawson Barclays | Hold | $31.0 | downgraded | Dec 1, 2023 |
| swayampakula ramakanth H.C. Wainwright | Hold | $31.26 | downgraded | Nov 30, 2023 |
| etzer darout BMO Capital | Hold | $31.0 | downgraded | Nov 30, 2023 |
| jonathan chang Leerink Partners | Hold | $31.26 | maintained | Nov 30, 2023 |
| kelly shi Jefferies | Hold | $31.0 | downgraded | Nov 30, 2023 |
| andy hsieh William Blair | Hold | None | downgraded | Nov 30, 2023 |
| james shin Deutsche Bank | Hold | $31.0 | downgraded | Nov 30, 2023 |
| asthika goonewardene Truist Financial | Hold | $31.0 | downgraded | Nov 30, 2023 |
| andrea tan Goldman Sachs | Hold | $17.0 | initiatedcoverage | Nov 20, 2023 |
| jay olson Oppenheimer | Hold | $16.0 | maintained | Nov 3, 2023 |
| boris peaker TD Cowen | Buy | None | maintained | Nov 2, 2023 |
| brian cheng J.P. Morgan | Buy | $22.0 | upgraded | Sep 13, 2023 |
| daniel wolle J.P. Morgan | Hold | $9.0 | maintained | Jan 23, 2023 |
| jessica fye J.P. Morgan | Hold | $8.0 | maintained | Mar 21, 2022 |
| kennen mackay RBC Capital | Hold | $6.0 | downgraded | Mar 21, 2022 |
| matt phipps William Blair | Buy | None | maintained | Jun 11, 2021 |
| john scott Cowen & Co. | Buy | None | reiterated | Dec 4, 2020 |
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.
When did it IPO
1989
Staff Count
277
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Mark Joseph Enyedy
Market Cap
$8.72B
In 2023, IMGN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IMGN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
IEP-USD
$21.54
LBRDA-USD
$61.37
LBRDK-USD
$60.87
DBX-USD
$23.86
OLED-USD
$181.76
LCID-USD
$3.7
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
